These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 23803104

  • 1. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY, Jia S, Zhang WH, Zhang Y, Kang Y, Li PS.
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [Abstract] [Full Text] [Related]

  • 2. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E, Seifu D, Tigneh W, Bokretsion Y, Bekele A, Abebe M, Sollie T, Merajver SD, Karlsson C, Karlsson MG.
    BMC Womens Health; 2018 Feb 14; 18(1):40. PubMed ID: 29444670
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K, Miyashita M, Ishida T, Suzuki A, Tada H, Watanabe G, Sato-Tadano A, Watanabe M, Ohuchi N.
    Breast Cancer; 2016 Mar 14; 23(2):310-7. PubMed ID: 25380989
    [Abstract] [Full Text] [Related]

  • 4. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M, Martinez S, Acevedo F, Oddo D, Artigas R, Camus M, Sanchez C.
    Asian Pac J Cancer Prev; 2014 Mar 14; 15(23):10277-80. PubMed ID: 25556461
    [Abstract] [Full Text] [Related]

  • 5. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 Mar 14; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.
    Clin Breast Cancer; 2012 Oct 14; 12(5):340-6. PubMed ID: 23040002
    [Abstract] [Full Text] [Related]

  • 7. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.
    J Natl Cancer Inst; 2009 May 20; 101(10):736-50. PubMed ID: 19436038
    [Abstract] [Full Text] [Related]

  • 8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M, South and South-East Swedish Breast Cancer Groups.
    Acta Oncol; 2017 Jan 20; 56(1):68-74. PubMed ID: 27762648
    [Abstract] [Full Text] [Related]

  • 9. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 20; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 10. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW.
    Breast; 2012 Feb 20; 21(1):50-7. PubMed ID: 21865043
    [Abstract] [Full Text] [Related]

  • 11. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
    Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X, Shen K.
    BMC Cancer; 2013 Aug 19; 13():390. PubMed ID: 23957561
    [Abstract] [Full Text] [Related]

  • 12. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.
    PLoS One; 2014 Aug 19; 9(1):e87032. PubMed ID: 24498016
    [Abstract] [Full Text] [Related]

  • 13. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
    Khokher S, Qureshi MU, Mahmood S, Nagi AH.
    Asian Pac J Cancer Prev; 2013 Aug 19; 14(5):3223-8. PubMed ID: 23803108
    [Abstract] [Full Text] [Related]

  • 14. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X, Zhu S, Fei X, Garfield DH, Wu J, Huang O, Li Y, Zhu L, He J, Chen W, Jin X, Shen K.
    BMC Cancer; 2015 Oct 30; 15():822. PubMed ID: 26514283
    [Abstract] [Full Text] [Related]

  • 15. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
    de Macêdo Andrade AC, Ferreira Júnior CA, Dantas Guimarães B, Pessoa Barros AW, Sarmento de Almeida G, Weller M.
    BMC Womens Health; 2014 Sep 12; 14():110. PubMed ID: 25216732
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.
    Breast Cancer; 2015 Mar 12; 22(2):185-91. PubMed ID: 23645542
    [Abstract] [Full Text] [Related]

  • 17. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
    Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A.
    Breast Cancer Res; 2014 Jun 20; 16(3):R65. PubMed ID: 24951027
    [Abstract] [Full Text] [Related]

  • 18. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T.
    Clin Transl Oncol; 2016 Oct 20; 18(10):996-1002. PubMed ID: 26742937
    [Abstract] [Full Text] [Related]

  • 19. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR.
    J Transl Med; 2019 Oct 03; 17(1):334. PubMed ID: 31581940
    [Abstract] [Full Text] [Related]

  • 20. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS.
    Saudi Med J; 2016 Feb 03; 37(2):137-41. PubMed ID: 26837394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.